ArticleScientific reports2020
Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Efficacy of intravitreal injection of anti-vascular endothelial growth factor as an adjunctive treatment for proliferative diabetic retinopathy before pars plana vitrectomy: a systematic evaluation and meta-analysis.International ophthalmology · 2025Pooled it
- Intravitreal anti-vascular endothelial growth factor agents as an adjunct for proliferative diabetic retinopathy: a systematic review and meta-analysis.BMC ophthalmology · 2025Pooled it
- Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial.Frontiers in public health · 2022Trial
- Perioperative anti-vascular endothelial growth factor treatment in diabetic vitrectomy: A narrative review.Indian journal of ophthalmology · 2026Review
- Retinal Outcomes in Diabetes: Antihyperglycemic Therapy, EWDR, and Perioperative Considerations.Biomedicines · 2026Review
- Adjuvant Anti-VEGF in Vitrectomy for Proliferative Diabetic Retinopathy: Current Evidence, Timing Considerations, and Clinical Implications.Current ophthalmology reports · 2026Article
- Proliferative diabetic retinopathy subtypes defined by immune defense and endothelial mitochondrial dysfunction.Signal transduction and targeted therapy · 2025Article
- Integrative Management of High-Risk Proliferative Diabetic Retinopathy: Precision Diagnostics via Ultra-Widefield Imaging and Therapeutic Strategies.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Combined Use of Anti-VEGF Drugs Before and During Pars Plana Vitrectomy for Severe Proliferative Diabetic Retinopathy.Ophthalmology and therapy · 2023Article
- 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept.Experimental and therapeutic medicine · 2023Article
- Effectiveness and safety of traditional Chinese medicine for diabetic retinopathy: A systematic review and network meta-analysis of randomized clinical trials.World journal of diabetes · 2023Article
- Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy.Life (Basel, Switzerland) · 2023Review
- Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy.Frontiers in endocrinology · 2023Article
- Global trends and performances in diabetic retinopathy studies: A bibliometric analysis.Frontiers in public health · 2023Article
- Surgical treatment for proliferative diabetic retinopathy with ocular albinism.International journal of ophthalmology · 2023Article
- Effect of intravitreal ranibizumab on fibrovascular membranes in patients with proliferative diabetic retinopathy.International journal of ophthalmology · 2022Article
- Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients.International journal of ophthalmology · 2022Article
- Differences in Vitreous Protein Profiles in Patients With Proliferative Diabetic Retinopathy Before and After Ranibizumab Treatment.Frontiers in medicine · 2022Article
- Preoperative laser reduces silicone oil use in primary diabetic vitrectomy.International journal of ophthalmology · 2022Article
- Pharmacotherapy as an adjunct to vitrectomy.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, controversies regarding the optimal time-point of anti-vascular endothelial growth factor (VEGF) pretreatment before pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR) still exist. To clarify this, we conducted a network meta-analysis, 26 randomized controlled trials including 1806 PDR patients were included. Compared with the sham group, performing anti-VEGF injection at preoperative (Pre-Op) 6 to 14 days could significantly improve post-operative best-corrected visual acuity (BCVA) and decrease the incidence of recurrent vitreous hemorrhage (VH). Meanwhile, it could significantly reduce the duration of surgery. Performing anti-VEGF injection at Pre-Op more than 14 days, 6 to 14 days or 1 to 5 days could significantly reduce the incidence of intra-operative bleeding, while no significant benefit existed at the end of PPV (P > 0.05). No significant difference existed between all those strategies and sham group in reducing the rate of silicone oil tamponade. Based on currently available evidence, performing the anti-VEGF pretreatment at pre-operative 6 to 14 days showed best efficacy in improving post-operative BCVA, reducing the duration of surgery and incidence of recurrent VH, it also achieves satisfactory effect in reducing the incidence of intra-operative bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.